hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06298695 id: 2012939 id: 10390022210010 type: OTHER_GRANT domain: ZonMw briefTitle: Schema Therapy for Treatment-resistant Anxiety Disorders acronym: PaDoLA overallStatus: NOT_YET_RECRUITING date: 2024-09-01 date: 2024-09-30 date: 2030-12-31 date: 2024-03-07 date: 2024-03-07 name: Amsterdam UMC, location VUmc class: OTHER name: ZonMw: The Netherlands Organisation for Health Research and Development name: ADF Stichting name: University of Amsterdam name: Maastricht University name: GGZ inGeest name: Pro Persona Mental Health Care Foundation name: Mondriaan name: GGNet name: GGZ Delfland briefSummary: The aim of this study is to assess the cost-effectiveness of schema therapy compared to treatment as usual (TAU) in patients with treatment-resistant anxiety disorders. In a multicenter randomized controlled trial, patients will be assigned to receive individual schema therapy (maximum of 40 sessions) or treatment as usual (control group) within one year. The primary outcome is the difference between ST and TAU conditions in anxiety symptoms as measured with the Beck Anxiety Inventroy (BAI) at post treatment. Secondary outcomes include quality of life, societal costs, general mental health, remission from the anxiety disorders and/or comorbid affective disorders, positive and negative effects of psychotherapy, schemas and schema modes, and satisfaction. Measurements take place at baseline and after 1, 3, 6, 12, 24 and 36 months (follow-up of two years). conditions: Anxiety Disorders studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: A multicenter parallel group randomized controlled clinical intervention trial primaryPurpose: TREATMENT masking: SINGLE whoMasked: OUTCOMES_ASSESSOR count: 172 type: ESTIMATED name: Individual Schema Therapy name: TAU measure: Changes in the severity of anxiety symptoms measure: Health-related quality of life measure: Mental health quality of life measure: Health care utilization and productivity losses measure: Remission from the primary anxiety disorder and from comorbid disorders measure: Screening for DSM-5 personality disorders measure: Assessment of DSM-5 personality disorders measure: Demographics measure: (Strength of) treatment preference measure: Assessment of childhood trauma measure: Assessment of autistic traits measure: Assessment of general mental health measure: Functioning and recovery in psychiatric patients measure: Early Maladaptive Schemas measure: Schema Modes measure: Positive and negative effects of psychotherapy measure: The level of satisfaction with the psychological treatment sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06298682 id: CCM1421 briefTitle: Characterization of Exosomes Platelets-released acronym: EXOPLT overallStatus: RECRUITING date: 2021-07-08 date: 2026-07-07 date: 2027-07-07 date: 2024-03-07 date: 2024-03-12 name: Centro Cardiologico Monzino class: OTHER name: Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico briefSummary: Extracellular vesicles (EVs) play a key role in cell-to-cell communication. They are small vesicles that contain rich molecular cargo. Recently, they have been proposed as biomarkers for clinical diagnostics. EVs include three classes: small EVs (exosomes), large EVs (microparticles), and apoptotic bodies. Platelet-derived EVs (PEVs) are the most abundant class in human blood and can actively participate in numerous physiological and pathological processes. The information about the role of platelet exosomes in cardiovascular disease and the effect of antiplatelet agents on their release and content is very limited. conditions: Platelet Thrombus studyType: OBSERVATIONAL observationalModel: OTHER timePerspective: OTHER count: 175 type: ESTIMATED measure: Characterization of exosomes released by activated platelet by Nanoparticle Tracking Analysis (NTA) and proteoma analysis measure: Characterization of exosomes released by activated platelet and exposed to platelet inhibitors by NTA and proteoma analysis measure: Platelet exosome profile emerged by NTA and proteoma analysis will be related with the "biographical" and "anthropometric" data of the subjects. sex: ALL minimumAge: 20 Years maximumAge: 60 Years stdAges: ADULT facility: Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico status: RECRUITING city: Milan country: Italy name: Daniele Prati role: CONTACT lat: 45.46427 lon: 9.18951 hasResults: False
nctId: NCT06298669 id: 10652 briefTitle: Biventricular Versus Right Ventricular Pacing overallStatus: SUSPENDED date: 2023-08-09 date: 2025-02 date: 2025-02 date: 2024-03-07 date: 2024-03-07 name: Indiana University class: OTHER briefSummary: The study is a randomized, single-blind crossover prospective study in which investigators will determine the clinical outcomes of cardiac resynchronization therapy (CRT) pacing modalities in patients with left ventricular assist devices (LVAD). Only patients are blinded. This is a small-scale study from which future larger scale randomized controls can be performed. The primary endpoint will be the effect of BiV and RV pacing setting on the 6-minute walk test. conditions: Heart Failure studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: CROSSOVER primaryPurpose: TREATMENT masking: SINGLE whoMasked: PARTICIPANT count: 28 type: ESTIMATED name: Biventricular Pacing name: Right Ventricular Pacing measure: 6 Minute Walk Test Performance measure: Serum NT-PRO-BNP measure: EQ-5D-3L sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Indiana University Health Methodist Hospital city: Indianapolis state: Indiana zip: 46202 country: United States lat: 39.76838 lon: -86.15804 hasResults: False
nctId: NCT06298656 id: ILBS-ACLF-17 briefTitle: Acute hemodynamiC Response To Carvedilol Predicts Survival in ACLF Patients overallStatus: NOT_YET_RECRUITING date: 2024-03-10 date: 2026-02-28 date: 2026-02-28 date: 2024-03-07 date: 2024-03-07 name: Institute of Liver and Biliary Sciences, India class: OTHER briefSummary: Clinically significant portal hypertension (CSPH) is defined as HVPG \>10 mmHg. Patients with CSPH are at risk of developing esophageal varices and clinical decompensation (variceal bleeding, ascites, jaundice, encephalopathy), which mark the transition from compensated stage to a stage of the disease (decompensated) associated with higher mortality (1). HVPG is calculated by subtracting the free hepatic venous pressure (FHVP), a measure of systemic pressure, from the wedged hepatic venous pressure (WHVP), a measure of hepatic sinusoidal pressure. HVPG is surrogate marker in many clinical applications such as gold standard test to evaluate presence and severity of portal hypertension (PHT) diagnosis, risk stratification, monitoring of the patients on beta blockers (2). Non selective beta-blockers like propranolol and carvedilol are indicated in adults for primary and secondary prophylaxis of variceal hemorrhage. Acute hemodynamic response to intravenous propranolol with HVPG values coming down to \<12 mm Hg or reduction to \>20% from baseline have been shown to be associated with reduced long term risk of variceal bleed. Hence we are planning the current work to study the Acute hemodynamiC response To Carvedilol predicts survival in ACLF patients - "ACT - C ACLF study conditions: Acute-On-Chronic Liver Failure studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 100 type: ESTIMATED name: No intervention measure: Predictive value of acute HVPG change by carvedilol for 28 day transplant free survival in patients of ACLF measure: Complications [PHT related bleed, AKI, infections, HE, Hypotension, Cardiac side effect] within 90 days measure: Transplant-free survival rate at 90 days measure: Correlation with evolution of AARC score by 2 week sex: ALL minimumAge: 18 Years maximumAge: 70 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Institute of Liver & Biliary Sciences (ILBS) city: New Delhi state: Delhi zip: 110070 country: India name: Garvit Mundra, MD role: CONTACT phone: 01146300000 email: garvitmundrailbs@gmail.com lat: 28.63576 lon: 77.22445 hasResults: False
nctId: NCT06298630 id: 2022-LTF-BRL-101 briefTitle: Long-term Follow-up Study of BRL-101 for TDT overallStatus: NOT_YET_RECRUITING date: 2024-12-08 date: 2038-08-20 date: 2038-10-15 date: 2024-03-07 date: 2024-03-22 name: Bioray Laboratories class: INDUSTRY name: First Affiliated Hospital of Guangxi Medical University name: Xiangya Hospital of Central South University name: Chinese Academy of Medical Sciences name: Nanfang Hospital, Southern Medical University name: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University name: The 923rd Hospital of Joint Logistics Support Force of People's Liberation Army name: Shenzhen Children 's Hospital briefSummary: Observe long-term safety risk and long-term efficacy after intravenous infusion of BRL-101 in TDT subjects. conditions: Thalassemia, Beta studyType: OBSERVATIONAL observationalModel: CASE_ONLY timePerspective: PROSPECTIVE count: 45 type: ESTIMATED name: Assessments measure: Incidence of hematologic malignancies measure: Frequency, grade, and relationship of SAEs sex: ALL minimumAge: 3 Years maximumAge: 35 Years stdAges: CHILD stdAges: ADULT facility: Nanfang Hospital, Southern Medical University city: Guangzhou state: Guangdong zip: 510006 country: China name: Xiaoqin Feng, phD role: CONTACT lat: 23.11667 lon: 113.25 facility: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University city: Guangzhou state: Guangdong zip: 510006 country: China name: Jianpei Fang, phD role: CONTACT lat: 23.11667 lon: 113.25 facility: Shenzhen Children 's Hospital city: Shenzhen state: Guangdong zip: 510006 country: China name: Sixi Liu, phD role: CONTACT lat: 22.54554 lon: 114.0683 facility: No. 923 Hospital of Joint Support Force of Chinese People 's Liberation Army Hospital city: Nanning state: Guangxi zip: 530021 country: China name: Xinhua Zhang, phD role: CONTACT lat: 22.81667 lon: 108.31667 facility: Xiangya Hospital of Central South University city: Changsha state: Hunan zip: 510510 country: China name: Bin Fu, PhD role: CONTACT lat: 28.19874 lon: 112.97087 facility: Tianjin Institute of Hematology city: Tianjin state: Tianjin zip: 300000 country: China name: Jun shi, PhD role: CONTACT lat: 39.14222 lon: 117.17667 facility: The First Affiliated Hospital of GUANGXI MEDICAL UNIVERSITY city: Guangxi zip: 530021 country: China name: Yongrong Lai, PhD role: CONTACT hasResults: False
nctId: NCT06298617 id: RC 27.1.2024 briefTitle: Systemic Inflammatory Indices as a Non-invasive Grading Modality for Endometriosis overallStatus: COMPLETED date: 2023-01-01 date: 2023-07-30 date: 2023-12-25 date: 2024-03-07 date: 2024-03-12 name: Benha University class: OTHER briefSummary: Endometriosis (EMs) is one of the commonest chronic inflammatory disorder affecting women and is characterized by the presence and growth of endometrial-like glandular epithelial and stromal cells outside the uterus leading to multiple clinical symptoms affecting patients quality of life and fertility with high recurrence rate . The systemic immune inflammatory index (SII) and systemic inflammatory response index (SIRI) are documented as prognostic serum biomarker in many kinds of cancer and for the need and outcomes of adjuvant therapies for various cancers . conditions: Endometriosis studyType: OBSERVATIONAL observationalModel: OTHER timePerspective: PROSPECTIVE count: 88 type: ACTUAL name: Diagnostic laparoscopy name: Full Blood Count (FBC) measure: Indices' ability to predict EM stage sex: FEMALE minimumAge: 25 Years maximumAge: 50 Years stdAges: ADULT facility: Benha University city: Banhā state: Al Qalyobia zip: 13511 country: Egypt lat: 30.45906 lon: 31.17858 hasResults: False
nctId: NCT06298604 id: IECED-12112023 briefTitle: Motorized Fine Needle Biopsy vs Standard Needles overallStatus: RECRUITING date: 2023-12-09 date: 2024-10-09 date: 2024-12-09 date: 2024-03-07 date: 2024-03-22 name: Instituto Ecuatoriano de Enfermedades Digestivas class: OTHER briefSummary: Recent improvements in punctures techniques and needles now allow for the collection of high-quality specimens comparable to core needle biopsy. A newly developed motorized fine needle biopsy (mFNB), the Precision-GI (Limaca, Israel) promises intact tissue acquisition without sample damage, relying on controlled axial tissue cutting and high-speed rotational coring for optimized tissue acquisition.
Given the advancement mentioned, the investigators aim to compare the performance of the mFNB with the standard needle during the acquisition of endoscopic ultrasound (EUS)-guided pancreatic and liver specimens through a prospective, interventional, single-center trial. The study will consist of two groups of patients: one assigned to the standard fine needle biopsy (FNB) and the other to the mFNB. The primary study outcomes will include sample quality (core integrity), and diagnostic accuracy. conditions: Pancreas Disease conditions: Liver Diseases studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Prospective, diagnostic,, cross-sectional study primaryPurpose: DIAGNOSTIC masking: SINGLE maskingDescription: Single masking, the pathologist will be blinded to the needle used for sample collection. whoMasked: CARE_PROVIDER count: 60 type: ESTIMATED name: EUS-guided standard fine needle biopsy name: EUS-guided motorized fine needle biopsy measure: Endoscopic ultrasound fine needle biopsy sample quality measure: Diagnostic accuracy according to histological analysis measure: Tissue blood contamination measure: Time efficiency during tissue acquisition measure: Rate of liver specimen adequacy measure: Rate of adverse events associated with the procedure measure: Quality of cytologic sample sex: ALL minimumAge: 18 Years maximumAge: 99 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Instituto Ecuatoriano de Enfermedades Digestivas (IECED) status: RECRUITING city: Guayaquil zip: 090505 country: Ecuador name: Carlos Robles-Medranda, MD FASGE role: CONTACT phone: +593989158865 email: carlosoakm@yahoo.es name: Carlos Robles-Medranda, MD FASGE role: PRINCIPAL_INVESTIGATOR name: Raquel Del Valle, MD role: SUB_INVESTIGATOR name: Maria Egas-Izquierdo, MD role: SUB_INVESTIGATOR name: Jorge Baquerizo-Burgos, MD role: SUB_INVESTIGATOR name: Domenica Cunto, MD role: SUB_INVESTIGATOR name: Juan Alcivar-Vasquez, MD role: SUB_INVESTIGATOR name: Daniela Tabacelia, MD role: SUB_INVESTIGATOR name: Martha Arevalo-Mora, MD role: SUB_INVESTIGATOR name: Miguel Puga-Tejada, MD role: SUB_INVESTIGATOR name: Gustavo Rubio, MD role: SUB_INVESTIGATOR name: Hannah Pitanga-Lukashok, MD role: SUB_INVESTIGATOR lat: -2.20584 lon: -79.90795 hasResults: False
nctId: NCT06298591 id: atrophic scar treatment briefTitle: The Efficacy of Combination Therapy in Atrophic Scars overallStatus: NOT_YET_RECRUITING date: 2024-03-15 date: 2027-03-15 date: 2027-03-15 date: 2024-03-07 date: 2024-03-07 name: Assiut University class: OTHER briefSummary: There are more than 100 million patients who develop scar formation caused by various factors, such as post-inflammatory acne and trauma (1). They often have physical, aesthetic, psychological, and social barriers. Scar tissue is naturally a stage of wound healing. Abnormal wound healing produces a spectrum of scar tissue types such as atrophic, hypertrophic, and keloid scars (2).
Ultrasound is a unique non-invasive and non-radiating medical imaging tool in the investigation of dermatological diseases by providing detailed anatomic and physiologic data of skin lesions and deeper soft tissue changes. Lesion size in three dimensions-lengths, width, and depth, morphology, the detailed anatomic information provided by sonography is useful to assessment of effect of different types of treatment modality to improve atrophic scar and avoid invasive assessment tools as punch biopsy for histopathological examination (6) conditions: Atrophic Scar studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 45 type: ESTIMATED name: co2 laser measure: change of dermal thickness in sonar and Vancouver scale sex: ALL minimumAge: 12 Years maximumAge: 70 Years stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06298578 id: Mobile Based Application briefTitle: The Utility of Mobile Based Application for Patient Reported Outcome Measures In Patients With Acetabular Fractures : A Randomized Clinical Trial overallStatus: NOT_YET_RECRUITING date: 2024-04-01 date: 2025-12-01 date: 2026-01-01 date: 2024-03-07 date: 2024-03-07 name: Assiut University class: OTHER briefSummary: The primary objective of this study is to validate the feasibility of a remote patient monitoring (RPM) system using Mobile App in terms of the frequency of data interruptions and patient acceptance.
The secondary objective is to Improve quality of life and early prediction of the complications. conditions: Acetabular Fracture studyType: OBSERVATIONAL observationalModel: ECOLOGIC_OR_COMMUNITY timePerspective: PROSPECTIVE count: 126 type: ESTIMATED measure: percentage of missed follow up data in both groups postoperatively through assessing the patient-reported outcome measures (PROMS) after surgery for a fracture of the acetabulum using the Arabic validated form of (SF-36) measure: Quality of life scoring (Arabic validated form of (SF-36) and early prediction of the complications sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06298565 id: ARGX-113-PASS-2208 briefTitle: A Non-interventional, Post-authorisation Safety Study of Patients Treated With Efgartigimod Alfa overallStatus: NOT_YET_RECRUITING date: 2024-06 date: 2034-06 date: 2034-06 date: 2024-03-07 date: 2024-03-07 name: argenx class: INDUSTRY briefSummary: This is a non-interventional, prospective, post authorization safety study. Patients with gMG who are expected to start treatment with efgartigimod at enrolment or are within their first cycle of efgartigimod at enrolment will be eligible to enroll into the efgartigimod cohort. Patients with gMG who have not been exposed to efgartigimod and for whom it is not planned to start treatment with efgartigimod at enrolment will be eligible to enroll into the non-efgartigimod cohort. conditions: Myasthenia Gravis studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 680 type: ESTIMATED name: efgartigimod measure: The overall long-term safety of efgartigimod including the occurrence of serious infections in generalized myasthenia gravis (gMG) patients treated with efgartigimod compared to gMG patients not exposed to efgartigimod sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06298552 id: ARGX-113-2308 id: 2024-511796-15-00 type: OTHER domain: CTIS number briefTitle: A Phase 3 Study to Evaluate the Efficacy and Safety of Efgartigimod IV in Patients With Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia Gravis acronym: ADAPT SERON overallStatus: RECRUITING date: 2024-04-16 date: 2025-07-25 date: 2027-07-23 date: 2024-03-07 date: 2024-04-23 name: argenx class: INDUSTRY briefSummary: The primary purpose of this study is to measure the efficacy and safety of efgartigimod intravenously (IV) compared to placebo in participants with Acetylcholine Receptor Binding Antibody (AChR-Ab) seronegative Generalized Myasthenia Gravis (gMG). Other objectives are to assess long-term efficacy, safety, and tolerability of efgartigimod.
* Part B: participants completing part A will receive open-label efgartigimod IV conditions: Generalized Myasthenia Gravis studyType: INTERVENTIONAL phases: PHASE3 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: DOUBLE whoMasked: PARTICIPANT whoMasked: INVESTIGATOR count: 110 type: ESTIMATED name: Efgartigimod IV name: Placebo IV measure: Myasthenia Gravis Activities of Daily Living (MG-ADL) total score change from baseline measure: Quantitative myasthenia gravis (QMG) total score change from baseline measure: Proportion of participants who are both MG-ADL and QMG responders sex: ALL stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: First Choice Neurology Boca Raton status: RECRUITING city: Boca Raton state: Florida zip: 33428 country: United States name: Brian Costell, MD role: CONTACT phone: 857-350-4834 email: clinicaltrials@argenx.com lat: 26.3669 lon: -80.13033 hasResults: False
nctId: NCT06298539 id: 21C308 briefTitle: Auditory Sensory Attenuation in Obesity acronym: Ud_SA_OB overallStatus: ACTIVE_NOT_RECRUITING date: 2023-03-01 date: 2024-12-31 date: 2024-12-31 date: 2024-03-07 date: 2024-03-12 name: Istituto Auxologico Italiano class: OTHER name: University of Turin, Italy briefSummary: The goal of this observational cross-sectional study is to test the sensory attenuation effect with auditory stimuli comparing women with obesity and healthy-weight women. Specifically, the study aims to test whether the sensory attenuation effect (i.e., the perceived loudness of a self-generated sound is weaker than when another person produces the same sound):
Participants will compare the loudness of target sound with a comparison tone, which can be prompt by the participant by pressing a button on their own will (i.e., individual context) or upon the experimenter\'s signal (i.e., interactive context); externally-generated sounds are produced in the opposite way. conditions: Obesity studyType: OBSERVATIONAL observationalModel: CASE_CONTROL timePerspective: CROSS_SECTIONAL count: 36 type: ESTIMATED measure: point of subjective equality (PSE) measure: cognitive empathy measure: interpersonal pleasure sex: FEMALE minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: IRCCS Istituto Auxologico Italiano, San Giuseppe Hospital city: Piancavallo state: VCO zip: 28824 country: Italy hasResults: False
nctId: NCT06298526 id: 21C307 briefTitle: Auditory Sensory Attenuation in Anorexia Nervosa acronym: UdSA_AN overallStatus: ACTIVE_NOT_RECRUITING date: 2023-03-01 date: 2024-02-29 date: 2024-12-31 date: 2024-03-07 date: 2024-03-12 name: Istituto Auxologico Italiano class: OTHER briefSummary: The goal of this observational cross-sectional study is to test the sensory attenuation effect with auditory stimuli comparing women affected by anorexia nervosa and healthy-weight women. Specifically, the study aims to test whether the sensory attenuation effect (i.e., the perceived loudness of a self-generated sound is weaker than when another person produces the same sound):
Participants will compare the loudness of target sound with a comparison tone, which can be prompt by the participant by pressing a button on their own will (i.e., individual context) or upon the experimenter\'s signal (i.e., interactive context); externally-generated sounds are produced in the opposite way. conditions: Anorexia Nervosa studyType: OBSERVATIONAL observationalModel: CASE_CONTROL timePerspective: CROSS_SECTIONAL count: 36 type: ESTIMATED measure: point of subjective equality (PSE) measure: cognitive empathy measure: interpersonal pleasure sex: FEMALE minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: IRCCS Istituto Auxologico Italiano, San Giuseppe Hospital city: Piancavallo state: VCO zip: 28824 country: Italy hasResults: False